Use of Synthetic Peptides and Anti-Idiotypes for Controlling Human Immunodeficiency Virus Infection
Abstract
This annual report describes our research effort in examining the use of synthetic peptides and anti-idiotypes (anti-Id) as two strategies for controlling human immunodeficiency virus (HIV) type 1 (HIV-1). Utilizing synthetic peptides to define Linear epitopes on HIV-1 gp160, we compared the fine specificity of the humoral immune response to HIV-1 infection in humans representing two geographically diverse populations. In addition, we examined the anti-gp160 fine specificity in HIV-1 infected chimpanzees and recombinant gp160 immunized mice. We attempted to correlate reactivity to selected gp160 epitopes defined by peptides with disease progression and/or in vitro neutralizing activity. Immunization studies were performed using selected synthetic peptides and novel adjuvant formulations to assess the ability to induce anti-HIV-1 gp160 responses in experimental animals. Murine monoclonal anti-Id reagents, both noninternal image and internal image in nature, were also developed and tested for the ability to induce anti-gp160 AB-3 responses in vivo. The molecular basis of monoclonal anti-ID was assessed by determining the variable (V) region gene sequence. These two strategies may serve to develop novel vaccination modalities and/or active immunization principles for controlling HIV-1 infection in vivo.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 30, 1991
- Accession Number
- ADA247960
Entities
People
- Ronald C. Kennedy
Organizations
- Texas Biomedical Research Institute